Summit Therapeutics to Participate in 2018 BTIG Healthcare Conference

Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for rare diseases and infectious diseases, announces that management will participate in one on one meetings at the 2018 BTIG Healthcare Conference on 27 February 2018 in Snowbird, UT, US.

About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit
Glyn Edwards / Richard Pye (UK office)	Tel:	44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office)		[phone]
Cairn Financial Advisers LLP (Nominated Adviser)	Tel:	[phone]
Liam Murray / Tony Rawlinson
N+1 Singer (Joint Broker)	Tel:	[phone]
Aubrey Powell / Jen Boorer
Panmure Gordon (Joint Broker)	Tel:	[phone]
Freddy Crossley, Corporate Finance
Tom Salvesen, Corporate Broking
MacDougall Biomedical Communications (US)	Tel:	[phone]
Karen Sharma		[e-mail]
Consilium Strategic Communications (UK)	Tel:	[phone]
Mary-Jane Elliott / Jessica Hodgson /		[e-mail]
Philippa Gardner / Rosie Phillips

-END-